{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3438"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Estimated by the number of patients who achieve a confirmed response at any time (with single agent ixazomib citrate or ixazomib citrate plus dexamethasone) divided by the number of evaluable patients. 95% confidence intervals for the true confirmed response rate will be calculated by the exact binomial method.","groups":[{"description":"Patients receive ixazomib citrate PO on days 1, 8, and 15. Patients with lack of minor response by the end of the second cycle or lack of partial response by the end of the fourth cycle also receive dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm A (Ixazomib Citrate and Dexamethasone)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2.5 years","title":"Confirmed Response Rate With the Addition of Dexamethasone (Arm A Only)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}